Your browser doesn't support javascript.
loading
Yardstick for the medical management of chronic rhinosinusitis.
Borish, Larry; Baroody, Fuad M; Kim, Margaret S; Lieberman, Jay A; Peters, Anju; Stevens, Whitney W; Bernstein, Jonathan A.
  • Borish L; Department of Medicine, Asthma and Allergic Disease Center, The University of Virginia, Charlottesville, Virginia.
  • Baroody FM; Department of Surgery (Otolaryngology-Head and Neck Surgery) and Pediatrics, The University of Chicago Medicine and the Comer Children's Hospital, Chicago, Illinois.
  • Kim MS; Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Lieberman JA; Division of Pulmonology, Allergy, & Immunology, Department of Pediatrics, The University of Tennessee Health Science Center, Memphis, Tennessee.
  • Peters A; Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Stevens WW; Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Bernstein JA; Division of Immunology-Allergy Section, Department of Internal Medicine, The University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address: jonathan.bernstein@uc.edu.
Ann Allergy Asthma Immunol ; 128(2): 118-128, 2022 02.
Article en En | MEDLINE | ID: mdl-34687874
ABSTRACT
Chronic rhinosinusitis (CRS) is an inflammatory condition of the paranasal sinuses defined by classic symptoms, imaging findings, or endoscopic findings. There are a growing number of emerging pharmacologic therapies being evaluated to treat patients with CRS, some of which have gained indication status in the United States. There have not been updated treatment guidelines published in the United States however since 2014. This document is meant to serve as an updated expert consensus document for the pharmacologic management of patients with CRS. We review available data focusing on prospective clinical trials on oral and intranasal corticosteroids, nasal irrigation, biologics, antibiotics, and allergy immunotherapy for CRS both with and without nasal polyposis, including specific therapies for aspirin-exacerbated respiratory disease-associated CRS and allergic fungal CRS. There are multiple options to treat CRS, and clinicians should be knowledgeable on the efficacy and risks of these available therapies. Allergists-immunologists now have various therapies available to treat patients with CRS.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Senos Paranasales / Sinusitis / Rinitis / Pólipos Nasales Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Senos Paranasales / Sinusitis / Rinitis / Pólipos Nasales Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article